Inflammation, Immunity, Vaccines for Helicobacter pylori infection

Helicobacter

Volumn 18, Issue S1, 2013, Pages 18-23

  Koch, Manuel ^a   Meyer, Thomas F ^a   Moss, Steven F ^b  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b BROWN UNIVERSITY   (United States)

Author keywords

Dendritic cells; Inflammasome; Macrophages; MALT lymphoma; T cells; Vaccine

Indexed keywords

ALKYL HYDROPEROXIDE REDUCTASE; ALPHAVBETA5 INTEGRIN; ALUMINUM POTASSIUM SULFATE; BETA DEFENSIN 3; CAGA PROTEIN; CATALASE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; FLAGELLIN; GAMMA GLUTAMYLTRANSFERASE; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 23; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MICRORNA 155; OXIDOREDUCTASE; PEROXIDASE; TRIPLE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREASE; UREASE A; VACUOLATING TOXIN;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; BACTERIAL CLEARANCE; CONJUGATION; CYTOKINE RELEASE; DENDRITIC CELL; EPITHELIUM CELL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; LARGE CELL LYMPHOMA; MACROPHAGE; MARGINAL ZONE LYMPHOMA; NONHUMAN; PATHOGENICITY ISLAND; PHAGOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SALMONELLA TYPHIMURIUM; STOMACH CANCER; STOMACH EPITHELIUM; TH17 CELL; TYPE IV SECRETION SYSTEM; UPREGULATION;

DENDRITIC CELLS; INFLAMMASOME; MACROPHAGES; MALT LYMPHOMA; T CELLS; VACCINE;

ANIMALS; BACTERIAL VACCINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY;

EID: 84883782172     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12073     Document Type: Review

References (51)

1. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 2007;449:862-6.
2. Jimenez-Soto LF, Kutter S, Sewald X, Ertl C, Weiss E, Kapp U, et al. Helicobacter pylori type IV secretion apparatus exploits beta1 integrin in a novel rgd-independent manner. PLoS Pathog 2009;5:e1000684.
3. Gorrell RJ, Guan J, Xin Y, Tafreshi MA, Hutton ML, McGuckin MA et al. A novel Nod1- and CagA-independent pathway of interleukin-8 induction mediated by the Helicobacter pylori type IV secretion system. Cell Microbiol 2013;15:554-70. [Epub ahead of print]
4. Wiedemann T, Hofbaur S, Tegtmeyer N, Huber S, Sewald N, Wessler S, et al. Helicobacter pylori cagl dependent induction of gastrin expression via a novel alphavbeta5-integrin-integrin linked kinase signalling complex. Gut 2012;61:986-96.
5. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004;5:1166-74.
6. Sycuro LK, Wyckoff TJ, Biboy J, Born P, Pincus Z, Vollmer W, Salama NR. Multiple peptidoglycan modification networks modulate Helicobacter pylori's cell shape, motility, and colonization potential. PLoS Pathog 2012;8:e1002603.
7. Watanabe T, Asano N, Fichtner-Feigl S, Gorelick PL, Tsuji Y, Matsumoto Y, et al. Nod1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF-3 signaling pathway. J Clin Invest 2010;120:1645-62.
8. Allison CC, Ferrand J, McLeod L, Hassan M, Kaparakis-Liaskos M, Grubman A, et al. Nucleotide oligomerization domain 1 enhances IFN-gamma signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity. J Immunol 2013;190:3706-15.
9. Kang DW, Hwang WC, Park MH, Ko GH, Ha WS, Kim KS et al. Rebamipide abolishes Helicobacter pylori caga-induced phospholipase d1 expression via inhibition of NFkappaB and suppresses invasion of gastric cancer cells. Oncogene 2012. [Epub ahead of print]
10. Papadakos KS, Sougleri IS, Mentis AF, Hatziloukas E, Sgouras DN. Presence of terminal EPIYA phosphorylation motifs in Helicobacter pylori CagA contributes to IL-8 secretion, irrespective of the number of repeats. PLoS ONE 2013;8:e56291.
11. Backert S, Naumann M. What a disorder: proinflammatory signaling pathways induced by Helicobacter pylori. Trends Microbiol 2010;18:479-86.
12. Barrozo RM, Cooke CL, Hansen LM, Lam AM, Gaddy JA, Johnson EM, et al. Functional plasticity in the type IV secretion system of Helicobacter pylori. PLoS Pathog 2013;9:e1003189.
13. Bauer B, Pang E, Holland C, Kessler M, Bartfeld S, Meyer TF. The Helicobacter pylori virulence effector CagA abrogates human beta-defensin 3 expression via inactivation of EGFR signaling. Cell Host Microbe 2012;11:576-86.
14. Bauer B, Wex T, Kuester D, Meyer T, Malfertheiner P. Differential expression of human beta defensin 2 and 3 in gastric mucosa of Helicobacter pylori-infected individuals. Helicobacter 2013;18:6-12.
15. Zhang L, Yu J, Wong CC, Ling TK, Li ZJ, Chan KM et al. Cathelicidin protects against Helicobacter pylori colonization and the associated gastritis in mice. Gene Ther 2013;20:751-60. [Epub ahead of print]
16. Fehlings M, Drobbe L, Moos V, Renner Viveros P, Hagen J, Beigier-Bompadre M, et al. Comparative analysis of the interaction of Helicobacter pylori with human dendritic cells, macrophages, and monocytes. Infect Immun 2012;80:2724-34.
17. Rad R, Ballhorn W, Voland P, Eisenacher K, Mages J, Rad L, et al. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 2009;136:2247-57.
18. Otani K, Tanigawa T, Watanabe T, Nadatani Y, Sogawa M, Yamagami H, et al. Toll-like receptor 9 signaling has anti-inflammatory effects on the early phase of Helicobacter pylori-induced gastritis. Biochem Biophys Res Commun 2012;426:342-9.
19. Smythies LE, Shen R, Bimczok D, Novak L, Clements RH, Eckhoff DE, et al. Inflammation anergy in human intestinal macrophages is due to smad-induced IkappaBalpha expression and NF-kappaB inactivation. J Biol Chem 2010;285:19593-604.
20. Cole TS, Zhang M, Standiford TJ, Newstead M, Luther J, Zhang J, et al. Irak-m modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells. Immunol Lett 2012;144:49-59.
21. Miszczyk E, Rudnicka K, Moran AP, Fol M, Kowalewicz-Kulbat M, Druszczynska M, et al. Interaction of Helicobacter pylori with c-type lectin dendritic cell-specific ICAM grabbing nonintegrin. J Biomed Biotechnol 2012;2012:206463.
22. Koch M, Mollenkopf HJ, Klemm U, Meyer TF. Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-damage induced apoptosis. Proc Natl Acad Sci USA 2012;109:E1153-62.
23. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. Dc-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 2012;122:1082-96.
24. Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, et al. Helicobacter pylori gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA 2013;110:3047-52.
25. Mitchell PJ, Afzali B, Fazekasova H, Chen D, Ali N, Powell N, et al. Helicobacter pylori induces in-vivo expansion of human regulatory T cells through stimulating interleukin-1beta production by dendritic cells. Clin Exp Immunol 2012;170:300-9.
26. Chang LL, Wang SW, Wu IC, Yu FJ, Su YC, Chen YP, et al. Impaired dendritic cell maturation and IL-10 production following H. pylori stimulation in gastric cancer patients. Appl Microbiol Biotechnol 2012;96:211-20.
27. Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD, Muller A. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1beta and IL-18. J Immunol 2012;188:3594-602.
28. Hitzler I, Kohler E, Engler DB, Yazgan AS, Muller A. The role of Th cell subsets in the control of Helicobacter infections and in T cell-driven gastric immunopathology. Front Immunol 2012;3:142.
29. Horvath DJ Jr, Washington MK, Cope VA, Algood HM. IL-23 contributes to control of chronic Helicobacter pylori infection and the development of T helper responses in a mouse model. Front Immunol 2012;3:56.
30. Serrano C, Wright SW, Bimczok D, Shaffer CL, Cover TL, Venegas A et al. Downregulated Th17 responses are associated with reduced gastritis in Helicobacter pylori-infected children. Mucosal Immunol 2013. [Epub ahead of print]
31. Serelli-Lee V, Ling KL, Ho C, Yeong LH, Lim GK, Ho B, Wong SB. Persistent Helicobacter pylori specific Th17 responses in patients with past H. pylori infection are associated with elevated gastric mucosal IL-1beta. PLoS ONE 2012;7:e39199.
32. Chen L, Li B, Yang WC, He JL, Li NY, Hu J, et al. A dominant CD4(+) T-cell response to Helicobacter pylori reduces risk for gastric disease in humans. Gastroenterology 2013;144:591-600.
33. Gonzalez-Rivera C, Algood HM, Radin JN, McClain MS, Cover TL. The intermediate region of Helicobacter pylori vacA is a determinant of toxin potency in a Jurkat T cell assay. Infect Immun 2012;80:2578-88.
34. Gray BM, Fontaine CA, Poe SA, Eaton KA. Complex T cell interactions contribute to Helicobacter pylori gastritis in mice. Infect Immun 2013;81:740-52.
35. Choi YJ, Kim N, Paik JH, Kim JM, Lee SH, Park YS et al. Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter 2013;18(3):197-205. [Epub ahead of print]
36. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-58.
37. Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012;119:4838-44.
38. Thorns C, Kuba J, Bernard V, Senft A, Szymczak S, Feller AC, Bernd HW. Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma. Virchows Arch 2012;460:371-7.
39. Saito Y, Suzuki H, Tsugawa H, Imaeda H, Matsuzaki J, Hirata K, et al. Overexpression of mir-142-5p and mir-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS ONE 2012;7:e47396.
40. Malfertheiner P, Selgrad M, Wex T, Bornschein J, Palla E, Del Giudice G, et al. Efficacy of an investigational recombinant antigen based vaccine against a CagA H. pylori infectious challenge in healthy volunteers (abstract). Gastroenterology 2012;142:S-184.
41. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine 2012;30:5310-5.
42. Altman E, Chandan V, Harrison BA, Veloso-Pita R, Li J, KuoLee R, et al. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an alpha-1, 6-glucan chain. Vaccine 2012;30:7332-41.
43. O'Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 2012;30:3876-84.
44. Stent A, Every AL, Ng GZ, Chionh YT, Ong LS, Edwards SJ, Sutton P. Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines. Vaccine 2012;30:7214-20.
45. + T cell epitopes on Lpp 20 of Helicobacter pylori. BMC Immunol 2012;13:68.
46. Yang WC, Chen L, Li HB, Li B, Hu J, Zhang JY, et al. Identification of two novel immunodominant UreB CD4(+) T cell epitopes in Helicobacter pylori infected subjects. Vaccine 2013;31:1204-9.
47. Li HB, Zhang JY, He YF, Chen L, Li B, Liu KY, et al. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine 2012;31:120-6.
48. Guo L, Liu K, Xu G, Li X, Tu J, Tang F, et al. Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a balb/c mice model. Appl Microbiol Biotechnol 2012;95:1437-44.
49. Sjokvist Ottsjo L, Flach CF, Clements J, Holmgren J, Raghavan S. The double mutant heat-labile toxin from Escherichia coli, lt (r192g/l211a) is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun 2013;81:1532-40.
50. Mori J, Vranac T, Smrekar B, Cernilec M, Serbec VC, Horvat S, et al. Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori. Vaccine 2012;30:5856-63.
51. Vermoote M, Van Steendam K, Flahou B, Smet A, Pasmans F, Glibert P, et al. Immunization with the immunodominant Helicobacter suis urease subunit b induces partial protection against H. suis infection in a mouse model. Vet Res 2012;43:72.